Why We’re Already Thinking Ahead to 2028 Part B Drug Price Negotiations

With all the attention around the Medicare Part D provisions in the Inflation Reduction Act (IRA), it’s easy to overlook the upcoming Part B drug price negotiations (just kidding, we haven’t forgotten).

Part B spending is relatively concentrated to a small number of covered drugs, though 15 products will be the subject of government scrutiny and negotiations in 2028. These will include single-source branded products or biologics without an approved generic or biosimilar, as well as small-molecule drugs that have been on the market for at least 9 years and biologics that have been licensed for at least 13 years.¹

Manufacturers will need to offer the newly negotiated maximum fair price (MFP) to Medicare beneficiaries, with Medicare reimbursing...